gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-









Title Post: gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Url Post: http://www.news.fluser.com/gn2wzw-%df%a3%e9%90%a8q%ca%adl-q-xmjvu0ryut%de%8fh-eta%d5%adk84bkuf1dvbgywpz%d6%ac-%cc%b2%d7%9bjvx8gnew%c8%89p%c9%95u%da%8cmkf%cb%b2-o%c9%ab%d8%a97v6umeua%cd%b4/
Link To Post : gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Still Got It! Seven PEOPLE's Sexiest Men Alive Hit Oscar Red Carpet





Years have passed for some of our favorites, but that didn't stop Ben Affleck, Richard Gere, Denzel Washington and more from looking stunning








Credit: George Pimentel/Getty



Updated: Monday Feb 25, 2013 | 01:30 PM EST




Subscribe Now




Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Dow, S&P slip after uncertain Italian election

NEW YORK (Reuters) - U.S. stocks mostly fell on Monday on fears that a divided parliament in Italy would get in the way of the country's reforms and hamper the euro zone's stability.


Election projections showed the center-right coalition led by former prime minister Silvio Berlusconi was leading in the race for the Italian Senate, contradicting initial exit polls and raising the specter of deadlock in parliament.


Earlier polls pointing to a center-left victory lifted stocks in Milan and other European markets on investors' belief that they would continue the path to pay down Italian debt, said Art Hogan, managing director of Lazard Capital Markets in New York.


"What we don't want to hear is a renewed fear about a euro- zone fracture," he said.


Last week, the benchmark S&P 500 closed below its 14-day moving average on Wednesday for the first time this year. At midday, the S&P 500 was trading just below that level, now near 1,515.


The index was, nonetheless, still near highs not seen in five years, as bets on a strong U.S. economy have given equities support. The S&P 500's slight fall last week was the first weekly drop after a seven-week string of gains.


Banks and other financial stocks led Monday's decline on concern about the sector's exposure to Italy's massive debt. The KBW Bank Index <.bkx> fell 0.7 percent.


The Dow Jones industrial average <.dji> slipped 18.58 points or 0.13 percent, to 13,981.99. The Standard & Poor's 500 <.spx> shed 2.30 points or 0.15 percent, to 1,513.30. But the Nasdaq Composite <.ixic> rose 3.03 points or 0.10 percent, to 3,164.85.


Barnes & Noble Inc shares climbed 11.9 percent to $15.12 after the bookseller's chairman offered to buy its declining retail business.


The Nasdaq received support from Amgen Inc , up 4.2 percent at $90.47, after a rival issued a voluntary recall of its only drug, an anemia treatment that competes with Amgen's top-selling red blood cell booster, Epogen.


The FTSEurofirst-300 index of top European shares <.fteu3> unofficially closed up 0.1 percent and Italy's main FTSE MIB <.ftmib> ended up 0.7 percent after earlier gaining near 4 percent.


U.S. equities will face a test with the looming debate over the so-called sequestration, U.S. government budget cuts that will take effect starting on Friday if lawmakers fail to reach an agreement over spending and taxes. The White House issued warnings about the harm the cuts are likely to inflict on the economy if enacted.


With 83 percent of the S&P 500 companies having reported results so far, 69 percent beat profit expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters, according to Thomson Reuters data.


Fourth-quarter earnings for S&P 500 companies are estimated to have risen 6 percent, according to the data, above a 1.9 percent forecast at the start of the earnings season.


(Editing by Kenneth Barry and Jan Paschal)



Read More..

App connects users around the globe to personal trainers via video






(Reuters) – For fitness enthusiasts who can’t make it to the gym a web-based app will bring group video classes, and some friends for motivation, to them.


Wello, an app that connects users with personal trainers for video-based workouts, has launched group classes for a range of activities, including yoga, Taekwondo and high-intensity interval training. Classes are led by certified trainers and are accessible to anyone around the globe with a webcam and an Internet connection.






“It’s that ability to join in on something last-minute and also to explore something new,” said Ann Scott Plante, co-founder of San Francisco-based company Wello.


Like traditional classes, the instructors in the video classes, which have three to five students, offer motivation and feedback. Users can join an existing class, or organize a new one with friends.


Students can see a video feed of each other in the app, along with a feed of the instructor, who can provide feedback to them during the class.


“Instead of watching a static video that could get boring, or isn’t necessarily built for you, we thought we would give people the opportunity to meet with a real person who would spend the whole workout with you and correct your form,” Plante said.


Trainers on the platform are professionally certified in the United States and their experience and reviews can be viewed online before booking a class.


Plante said that by comparison to a traditional in-person class, trainers in the video class give more verbal instructions to make it easier to follow along and because they cannot physically adjust the students.


Although trainers can offer personal fitness classes with a video calling service such as Skype, Plante said the scheduling, payment and review features of Wello make it appealing for both instructors and users looking for a workout.


Wello, is available on the web with classes starting at under $ 10 per class. The company, which launched in July 2012, is working on iPad and television apps.


(Reporting by Natasha Baker in Toronto; Editing by Patricia Reaney and Eric Beech)


Internet News Headlines – Yahoo! News





Title Post: App connects users around the globe to personal trainers via video
Url Post: http://www.news.fluser.com/app-connects-users-around-the-globe-to-personal-trainers-via-video/
Link To Post : App connects users around the globe to personal trainers via video
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Tiger Woods, Elin Nordegren Reunite with Kids: Report















02/24/2013 at 01:55 PM EST







Elin Nordegren and Tiger Woods, in their married days


David Cannon/Getty


Tiger Woods and Elin Nordegren, having finalized their divorce in August 2010, haven't been seen in each other's company for ages – but that changed on Saturday, according to TMZ.com.

The website reports that the two were both in Jupiter, Fla., for a local youth sports event. The golfer showed up first, with the couple's son and daughter, Charlie and Sam. Nordegren followed an hour later.

Their reunion was described as cordial, though after an hour they reportedly left in her car in order to escape attention.

Since the bitter breakup of their "irretrievably broken" marriage, Woods, 37, has been seen with Lindsey Vonn, while Nordgren, 33, broke up a year ago with businessman Jamie Dingman.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.


Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.


Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.


"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.


Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.


But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.


National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.


"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.


OPTIONS BULLS TARGET GAINS


The spending cuts, if they go ahead, could hit the defense industry particularly hard.


Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.


Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.


"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.


The stock ended up 0.6 percent at $88.12 on Friday.


If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.


General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.


EYES ON GDP DATA, APPLE


The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.


U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.


Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.


Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.


On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.


(Additional reporting by Doris Frankel; Editing by Kenneth Barry)



Read More..

PayPal takes mobile payment service to Europe






SAN FRANCISCO (Reuters) – PayPal launched a European version of its PayPal Here mobile payments service for small merchants on Thursday as the online payments division of eBay Inc steps up competition with rivals, including Square Inc.


PayPal unveiled a new device, about the size of a smartphone, that allows small merchants to accept credit and debit cards under a more-stringent and complex system in Europe known as Chip and PIN.






The gadget connects to a new PayPal app that merchants can run on Apple Inc iPhones and Android-based smartphones.


PayPal said it will launch the service in the United Kingdom this summer, but plans to release it in other European countries later.


PayPal is the largest online payments business, but it is battling with a host of well-funded start-ups that are chipping away at its dominance.


Square, headed by Twitter co-founder Jack Dorsey, attracted thousands of small merchants in recent years by offering a free card reader that attaches to smartphones and handles payments for a flat 2.75 percent fee.


Last year, PayPal launched a rival service called PayPal Here in the United States and several other countries, including Japan and Australia.


The new European version of PayPal Here comes with a different device designed from scratch by the company’s U.K. team because of the more complex Chip and PIN system in the region. The approach in the United States, which relies on older magnetic stripes on cards, is considered simpler but potentially less secure.


“Trying to figure out how to make Chip and PIN to work in these devices has been hard,” said Rick Oglesby, a payments industry expert at Aite Group. “The gadgets so far have been fairly expensive and big and clunky.”


Square has yet to launch a service in Europe. It expanded into Canada last year, but that market does not require smaller merchants to use Chip and PIN technology yet, Oglesby noted.


PayPal said on Thursday that it will charge merchants for the European PayPal Here device. It did not say what the price will be, but a spokesman noted that it will be a “nominal” fee.


The company also plans to charge a per-fee transaction that will be similar to the 2.75 percent it charges small merchants in United States.


“For Chip and PIN devices, it’s not realistic to bring the cost down to zero,” Oglesby said. “That tends to temper the demand a little bit. But it also weeds out really small merchants and individuals who won’t use it as much.”


(Reporting By Alistair Barr. Editing by Andre Grenon)


Gadgets News Headlines – Yahoo! News





Title Post: PayPal takes mobile payment service to Europe
Url Post: http://www.news.fluser.com/paypal-takes-mobile-payment-service-to-europe/
Link To Post : PayPal takes mobile payment service to Europe
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Beyoncé & Blue Ivy Made Readers Smile















02/23/2013 at 01:35 PM EST



What's on the minds of PEOPLE readers this week? We love getting your feedback, and as always, you weighed in with plenty of strong reactions.

From your love of a new photos of Beyoncé's growing daughter Blue Ivy to your sadness over the suicide of country star Mindy McCready, readers responded to what made them mad, sad and also what kept them laughing out loud.

Check out the articles with the top reactions on the site this week, and keep clicking on the emoticons at the bottom of every story to tell us what you think!

LoveThere is no doubt the baby Blue Ivy is a Daddy's girl as new snaps of the child and her mother Beyoncé revealed this week. While her famous parents have kept her out of the spotlight, a photo of Blue Ivy, now 1, was apparently leaked from Beyoncé's HBO documentary, showing mom and daughter sharing the same photogenic smile.

LOLMeanwhile, seeing Taylor Swift in a very Beyoncé-esque costume at the Brit Awards drew some amusement from readers who wondered if Sasha Fierce now has a pop-country cousin.

Wow Chaz Bono has quickly followed through on his goal to lose significant weight, and readers were wowed by inspirational photos that saw him significantly trimmer and 43 pounds lighter. "I've been sticking to a really strict diet," he tells PEOPLE. "It's not any type of starvation thing. I'm just cutting out a lot of stuff and eating primarily protein and vegetables and fruit."

Angry Readers told us they were angered by Kim Kardashian's maternity style as she continues her habit of wearing tight-fitting fashion, even as her pregnancy has moved into its second trimester. Mom-to-be Kardashian, 32, defended her hourglass shape and its limitations with clothes. "I think because I have big boobs it could make me look heavier if I don't, like, show off my waist or something," she told Du Jour magazine.

SadCountry singer Mindy McCready's tragic suicide at 37 saddened readers. After years of dealing with addiction and legal problems, McCready killed herself at her Arkansas home, leaving behind son Zander, 6, with her ex Billy McKnight, and son Zayne, just 10 months.

Check back next week for another must-read roundup, and see what readers are reacting to every day here.

Beyoncé & Blue Ivy Made Readers Smile| Babies, Death, Music News, Beyonce Knowles, Chaz Bono, Kim Kardashian, Mindy Mccready, Taylor Swift

Taylor Swift at the Brit Awards (right) and Beyoncé at the Super Bowl

Getty; PictureGroup

Read More..